Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 28, 2014, 121 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $341.00 to $1,468,820,910.70.

Highlighted Stocks Traded by Insiders:

Apollo Investment (AINV) - FREE Research Report

Puleo Frank C, who is Director at Apollo Investment, bought 3,087 shares at $8.38 on May 28, 2014. Following this transaction, the Director owned 13,555 shares meaning that the stake was boosted by 29.49% with the 3,087-share transaction.

Historical insider transactions for Apollo Investment go as follows:

  • 4-Week # shares bought: 10,500
  • 12-Week # shares bought: 10,500
  • 24-Week # shares bought: 20,500

The average volume for Apollo Investment has been 2.7 million shares per day over the past 30 days. Apollo Investment has a market cap of $2.0 billion and is part of the financial sector and financial services industry. Shares are down 1.47% year-to-date as of the close of trading on Wednesday.

Apollo Investment Corporation is business development company and operates as a closed-end management investment company. The company invests in middle market companies. It provides direct equity capital, mezzanine and senior secured loans, and subordinated debt and loans. The stock currently has a dividend yield of 9.63%. The company has a P/E ratio of 7.0. Currently, there are 5 analysts who rate Apollo Investment a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AINV - FREE

TheStreet Quant Ratings rates Apollo Investment as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, notable return on equity and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Apollo Investment Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Impax Laboratories (IPXL) - FREE Research Report

Terreri Peter R, who is Director at Impax Laboratories, sold 3,000 shares at $28.00 on May 28, 2014. Following this transaction, the Director owned 41,520 shares meaning that the stake was reduced by 6.74% with the 3,000-share transaction.

The shares most recently traded at $27.93, down $0.07, or 0.25% since the insider transaction. Historical insider transactions for Impax Laboratories go as follows:

  • 4-Week # shares sold: 282,701
  • 12-Week # shares sold: 286,701
  • 24-Week # shares sold: 288,201

The average volume for Impax Laboratories has been 772,200 shares per day over the past 30 days. Impax Laboratories has a market cap of $2.0 billion and is part of the health care sector and drugs industry. Shares are up 11.46% year-to-date as of the close of trading on Wednesday.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products; and develops and markets branded products. The company operates through two segments, Global Pharmaceuticals Division and Impax Pharmaceutical Division. The company has a P/E ratio of 2826.0. Currently, there are 2 analysts who rate Impax Laboratories a buy, 2 analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPXL - FREE

TheStreet Quant Ratings rates Impax Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Impax Laboratories Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

McKesson (MCK) - FREE Research Report

Irby Alton F Iii, who is Director at McKesson, sold 4,000 shares at $182.73 on May 28, 2014. Following this transaction, the Director owned 11,728 shares meaning that the stake was reduced by 25.43% with the 4,000-share transaction.

The shares most recently traded at $186.97, up $4.24, or 2.27% since the insider transaction. Historical insider transactions for McKesson go as follows:

  • 24-Week # shares sold: 1,223

The average volume for McKesson has been 1.4 million shares per day over the past 30 days. McKesson has a market cap of $42.3 billion and is part of the services sector and wholesale industry. Shares are up 13.21% year-to-date as of the close of trading on Wednesday.

McKesson Corporation delivers pharmaceuticals, medical supplies, and health care information technologies to the healthcare industry in the United States and internationally. The company operates in two segments, McKesson Distribution Solutions and McKesson Technology Solutions. The stock currently has a dividend yield of 0.52%. The company has a P/E ratio of 31.4. Currently, there are 12 analysts who rate McKesson a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MCK - FREE

TheStreet Quant Ratings rates McKesson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full McKesson Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null